IRS Notice 2023-63, published on September 8, 2023, presents extensive, and somewhat contentious, guidelines on the capitalization and amortization of research and experimentation expenses under section 174. The notice is likely to evoke substantial discussion and commentary within the legal and business communities, given its broad implications on R&D tax relief for major corporations and firms.
At its core, Notice 2023-63 provides instruction on the treatment of research and experimentation (R&E) expenditures. It sets out when and how companies should capitalize R&E costs, and how these should be factored into financial reporting and tax calculations. Some critics argue that the new rules could curb R&D activities by increasing the tax burden on these functions.
With a complexity that matches its potential controversy, Notice 2023-63 is an issue that legal professionals in corporations worldwide cannot afford to ignore. As the government and businesses try to strike the right balance in encouraging innovation without compromising fiscal responsibility, it’s important for legal teams to understand how these capitalization requirements can impact their organizations.
The in-depth guidance captured within this notice was put together by Fenwick & West LLP. Their insights offer a crucial tool for companies to stay ahead of this potentially game-changing move in tax law.
For the full details on Notice 2023-63 and its implications, refer to the comprehensive guide by
Fenwick & West LLP.